BUSINESS

Lilly Japan Set for Leading Spot in All Core Areas in 2025, “No Plan to Replicate” Redundancy Program: Chief

April 14, 2021
Eli Lilly Japan aims to be a leading company in all of its five key strategic areas by 2025, anticipating an “unprecedented number” of new drug approvals and indications coming over the next five years, President Simone Thomsen told Jiho…

To read the full story

Related Article

BUSINESS

By Ludwig Kanzler

As reported previously, Reed Maurer passed away on August 30 due to complications from pneumonia. He was approaching his 84th birthday.Reed has been a driver of the international pharma community in Japan like nobody else. Arriving over fifty years ago…

By Takashi Ohama

Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…